Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aya Kita

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Leukemia Research|June 11, 2013
Combination of YM155, a survivin suppressant with a STAT3 inhibitor: a new strategy to treat diffuse large B-cell lymphomaNaoki Kaneko, Aya Kita, Kentaro Yamanaka, et al.
Expert Review of Endocrinology & Metabolism|February 13, 2019
Notch-Hes signaling in pituitary developmentMasato Hojo, Aya Kita, Ryoichiro Kageyama, et al.
Biological & Pharmaceutical Bulletin|January 17, 2014
Synergistic antitumor activities of sepantronium bromide (YM155), a survivin suppressant, in combination with microtubule-targeting agents in triple-negative breast cancer cellsNaoki Kaneko, Kentaro Yamanaka, Aya Kita, et al.
Nuclear Medicine and Biology|July 25, 2018
Predicting response to sepantronium bromide (YM155), a survivin suppressant, by PET imaging with [<sup>11</sup>C]YM155Keisuke Mitsuoka, Aya Kita, Yoshihiro Murakami, et al.
International Journal of Oncology|June 16, 2011
YM155, a selective survivin suppressant, inhibits tumor spread and prolongs survival in a spontaneous metastatic model of human triple negative breast cancerKentaro Yamanaka, Mari Nakata, Naoki Kaneko, et al.
Pharmaceutical Research|July 19, 2014
Formulation design and evaluation of liposomal sepantronium bromide (YM155), a small-molecule survivin suppressant, based on pharmacokinetic modeling and simulationKohsuke Shakushiro, Hiroki Kawano, Mari Nakata, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 4, 2014
Combination of YM155, a survivin suppressant, with bendamustine and rituximab: a new combination therapy to treat relapsed/refractory diffuse large B-cell lymphomaNaoki Kaneko, Keisuke Mitsuoka, Nobuaki Amino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2011
Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma modelsKentaro Yamanaka, Takahito Nakahara, Tomohiro Yamauchi, et al.
Brain Research|September 9, 2015
Hes1 and Hes5 are required for differentiation of pituicytes and formation of the neurohypophysis in pituitary developmentMasanori Goto, Masato Hojo, Mitsushige Ando, et al.
Journal of Molecular Endocrinology|October 12, 2018
The proneural bHLH genes Mash1, Math3 and NeuroD are required for pituitary developmentMitsushige Ando, Masanori Goto, Masato Hojo, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Leukemia Research|June 11, 2013
Combination of YM155, a survivin suppressant with a STAT3 inhibitor: a new strategy to treat diffuse large B-cell lymphomaNaoki Kaneko, Aya Kita, Kentaro Yamanaka, et al.
Expert Review of Endocrinology & Metabolism|February 13, 2019
Notch-Hes signaling in pituitary developmentMasato Hojo, Aya Kita, Ryoichiro Kageyama, et al.
Biological & Pharmaceutical Bulletin|January 17, 2014
Synergistic antitumor activities of sepantronium bromide (YM155), a survivin suppressant, in combination with microtubule-targeting agents in triple-negative breast cancer cellsNaoki Kaneko, Kentaro Yamanaka, Aya Kita, et al.
Nuclear Medicine and Biology|July 25, 2018
Predicting response to sepantronium bromide (YM155), a survivin suppressant, by PET imaging with [<sup>11</sup>C]YM155Keisuke Mitsuoka, Aya Kita, Yoshihiro Murakami, et al.
International Journal of Oncology|June 16, 2011
YM155, a selective survivin suppressant, inhibits tumor spread and prolongs survival in a spontaneous metastatic model of human triple negative breast cancerKentaro Yamanaka, Mari Nakata, Naoki Kaneko, et al.
Pharmaceutical Research|July 19, 2014
Formulation design and evaluation of liposomal sepantronium bromide (YM155), a small-molecule survivin suppressant, based on pharmacokinetic modeling and simulationKohsuke Shakushiro, Hiroki Kawano, Mari Nakata, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 4, 2014
Combination of YM155, a survivin suppressant, with bendamustine and rituximab: a new combination therapy to treat relapsed/refractory diffuse large B-cell lymphomaNaoki Kaneko, Keisuke Mitsuoka, Nobuaki Amino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2011
Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma modelsKentaro Yamanaka, Takahito Nakahara, Tomohiro Yamauchi, et al.
Brain Research|September 9, 2015
Hes1 and Hes5 are required for differentiation of pituicytes and formation of the neurohypophysis in pituitary developmentMasanori Goto, Masato Hojo, Mitsushige Ando, et al.
Journal of Molecular Endocrinology|October 12, 2018
The proneural bHLH genes Mash1, Math3 and NeuroD are required for pituitary developmentMitsushige Ando, Masanori Goto, Masato Hojo, et al.
Pageof 3